CJ
REGN icon

Caitlin John’s Regeneron Pharmaceuticals REGN Stock Holding History

Caitlin John’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Hold
0
– – – 922
2025
Q4 		– Sell
-61
Closed -$41.4K – 911
2025
Q3 		$34.3K Buy
+61
New +$34.5K 0.02% 313

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Caitlin John's REGN Position: Q1 2026 in Review

Caitlin John held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 0 shares worth $75. The position accounts for ﹤0.01% of the portfolio, ranked #922.

Caitlin John first reported a position in REGN in Q3 2025 and has held it in 1 quarter since. The position peaked at $34.3K in Q3 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Caitlin John held 0 shares of Regeneron Pharmaceuticals worth $75 as of Q1 2026.
  • Caitlin John left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Caitlin John's portfolio in Q1 2026, its #922 holding.
  • Caitlin John first reported a position in Regeneron Pharmaceuticals in Q3 2025 and has held it in 1 quarter since.
  • Caitlin John's Regeneron Pharmaceuticals position peaked at $34.3K in Q3 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Caitlin John's 13F filing for Q1 2026, filed 13 May 2026.